Clinical Trial Update: Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating ceralasertib priming followed by durvalumab and nab-paclitaxel in metastatic triple-negative breast cancer; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Ceralasertib (ceralasertib)
• Durvalumab (durvalumab)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: IFOM ETS - The AIRC Institute of Molecular Oncology | Conditions: Triple Negative Breast Cancer Metastatic | Phase 2 | Status: RECRUITING